Mariner LLC Has $40.56 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Mariner LLC increased its position in shares of Pfizer Inc. (NYSE:PFE) by 12.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,528,785 shares of the biopharmaceutical company’s stock after buying an additional 169,712 shares during the quarter. Mariner LLC’s holdings in Pfizer were worth $40,558,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. PSI Advisors LLC grew its holdings in shares of Pfizer by 1.4% during the fourth quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company’s stock valued at $738,000 after buying an additional 385 shares during the last quarter. Patriot Financial Group Insurance Agency LLC boosted its stake in Pfizer by 1.0% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company’s stock valued at $1,027,000 after purchasing an additional 391 shares during the last quarter. D Orazio & Associates Inc. raised its stake in shares of Pfizer by 5.5% in the fourth quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company’s stock worth $200,000 after purchasing an additional 391 shares during the last quarter. Lipe & Dalton boosted its position in shares of Pfizer by 17.7% during the fourth quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company’s stock valued at $71,000 after buying an additional 400 shares during the last quarter. Finally, Oliver Luxxe Assets LLC raised its position in Pfizer by 2.2% in the 4th quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company’s stock valued at $499,000 after buying an additional 401 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. UBS Group reduced their price objective on Pfizer from $28.00 to $24.00 and set a “neutral” rating for the company in a research note on Tuesday, April 8th. The Goldman Sachs Group reiterated a “neutral” rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Finally, Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $31.07.

Insider Buying and Selling

In other news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.06% of the stock is currently owned by insiders.

Pfizer Price Performance

Pfizer stock opened at $22.45 on Wednesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The firm has a market capitalization of $127.30 billion, a P/E ratio of 15.92, a PEG ratio of 0.64 and a beta of 0.67. The business has a fifty day moving average price of $25.09 and a 200-day moving average price of $26.31.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter last year, the company earned $0.10 EPS. The firm’s revenue was up 24.7% compared to the same quarter last year. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.